{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,3,6]],"date-time":"2026-03-06T03:40:02Z","timestamp":1772768402192,"version":"3.50.1"},"reference-count":46,"publisher":"Informa UK Limited","issue":"7","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Expert Opinion on Investigational Drugs"],"published-print":{"date-parts":[[2006,7]]},"DOI":"10.1517\/13543784.15.7.823","type":"journal-article","created":{"date-parts":[[2006,6,21]],"date-time":"2006-06-21T08:25:50Z","timestamp":1150878350000},"page":"823-828","source":"Crossref","is-referenced-by-count":39,"title":["Pirfenidone for the treatment of idiopathic pulmonary fibrosis"],"prefix":"10.1517","volume":"15","author":[{"given":"Sabina A","family":"Antoniu","sequence":"first","affiliation":[{"name":"Clinic of Pulmonary Disease, 30 Dr I Cihac Street, 700115, Iasi, Romania."}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"301","published-online":{"date-parts":[[2006,6,21]]},"reference":[{"key":"e_1_3_1_2_1","first-page":"1671","volume":"5","author":"THANNICKAL","year":"2004","unstructured":"THANNICKAL VJ, FLAHERTY KR, MARTINEZ FJ, LYNCH JP III: Idiopathic pulmonary fibrosis: emerging concepts on pharmacotherapy. Expert Opin. Pharmacother. (2004) 5(8):1671-1686.","journal-title":"Expert"},{"key":"e_1_3_1_3_1","first-page":"646","volume":"161","author":"AMERICAN THORACIC SOCIETY","year":"2000","unstructured":"AMERICAN THORACIC SOCIETY: Idiopathic pulmonary fibrosis: diagnosis and treatment. International consensus statement. American Thoracic Society (ATS), and the European Respiratory Society (ERS). Am. J. Respir. Crit. Care Med. (2000) 161(2 Part 1):646-664.","journal-title":"Am. J."},{"key":"e_1_3_1_4_1","first-page":"693","volume":"26","author":"BOUROS","year":"2005","unstructured":"BOUROS D, ANTONIOU KM: Current and future therapeutic approaches in idiopathic pulmonary fibrosis. Eur. Respir. J. (2005) 26(4):693-702.","journal-title":"Eur"},{"key":"e_1_3_1_5_1","first-page":"1063","volume":"157","author":"GAY","year":"1998","unstructured":"GAY SE, KAZEROONI EA, TOEWS GB et al.: Idiopathic pulmonary fibrosis: predicting response to therapy and survival. Am. J. Respir. Crit. Care Med. (1998) 157(4 Part 1):1063-1072.","journal-title":"Am. J."},{"key":"e_1_3_1_6_1","first-page":"1025","volume":"164","author":"KING","year":"2001","unstructured":"KING TE Jr, SCHWARZ MI, BROWN K et al.: Idiopathic pulmonary fibrosis: relationship between histopathologic features and mortality. Am. J. Respir. Crit. Care Med. (2001) 164(6):1025-1032.","journal-title":"Am. J."},{"key":"e_1_3_1_7_1","first-page":"1171","volume":"164","author":"KING","year":"2001","unstructured":"KING TE Jr, TOOZE JA, SCHWARZ MI, BROWN KR, CHERNIACK RM: Predicting survival in idiopathic pulmonary fibrosis: scoring system and survival model. Am. J. Respir. Crit. Care Med. (2001) 164(7):1171-1181.","journal-title":"Am. J."},{"key":"e_1_3_1_8_1","first-page":"367","volume":"291","author":"IYER","year":"1999","unstructured":"IYER SN, GURUJEYALAKSHMI G, GIRI SN: Effects of pirfenidone on transforming growth factor-\u03b2 gene expression at the transcriptional level in bleomycin hamster model of lung fibrosis. J. Pharmacol. Exp. Ther. (1999) 291(1):367-373.","journal-title":"J."},{"key":"e_1_3_1_9_1","doi-asserted-by":"publisher","DOI":"10.1016\/S0002-9343(00)00711-7"},{"key":"e_1_3_1_10_1","doi-asserted-by":"publisher","DOI":"10.1136\/thx.53.6.469"},{"key":"e_1_3_1_11_1","first-page":"291","volume":"144","author":"RAGHU","year":"1991","unstructured":"RAGHU G, DEPASO WJ, CAIN K et al.: Azathioprine combined with prednisone in the treatment of idiopathic pulmonary fibrosis: a prospective double-blind, randomized, placebo-controlled clinical trial. Am. Rev. Respir. Dis. (1991) 144(2):291-296.","journal-title":"Am. Rev."},{"key":"e_1_3_1_12_1","doi-asserted-by":"publisher","DOI":"10.1378\/chest.117.6.1619"},{"key":"e_1_3_1_13_1","doi-asserted-by":"publisher","DOI":"10.1378\/chest.125.6.2169"},{"key":"e_1_3_1_14_1","first-page":"L1255","volume":"285","author":"SEGEL","year":"2003","unstructured":"SEGEL MJ, IZBICKI G, COHEN PY et al.: Role of interferon-\u03b3 in the evolution of murine bleomycin lung fibrosis. Am. J. Physiol. Lung Cell Mol. Physiol. (2003) 285(6):L1255-L1262.","journal-title":"Am. J."},{"key":"e_1_3_1_15_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa030511"},{"key":"e_1_3_1_16_1","first-page":"L121","volume":"286","author":"LIU","year":"2004","unstructured":"LIU RM, LIU Y, FORMAN HJ, OLMAN M, TARPEY MM: Glutathione regulates transforming growth factor-\u03b2-stimulated collagen production in fibroblasts. Am. J. Physiol. Lung Cell Mol. Physiol. (2004) 286(1):L121-L128.","journal-title":"Am. J."},{"key":"e_1_3_1_17_1","first-page":"79","volume":"3","author":"CANTIN","year":"1990","unstructured":"CANTIN AM, LARIVEE P, BEGIN RO: Extracellular glutathione suppresses human lung fibroblast proliferation. Am. J. Respir. Cell Mol. Biol. (1990) 3(1):79-85.","journal-title":"Am. J."},{"key":"e_1_3_1_18_1","first-page":"845","volume":"4","author":"SHAHZEIDI","year":"1991","unstructured":"SHAHZEIDI S, SARNSTRAND B, JEFFERY PK, McANULTY RJ, LAURENT GJ: Oral N-acetylcysteine reduces bleomycin-induced collagen deposition in the lungs of mice. Eur. Respir. J. (1991) 4(7):845-852.","journal-title":"Eur"},{"key":"e_1_3_1_19_1","first-page":"431","volume":"7","author":"MEYER","year":"1994","unstructured":"MEYER A, BUHL R, MAGNUSSEN H: The effect of oral N-acetylcysteine on lung glutathione levels in idiopathic pulmonary fibrosis. Eur. Respir. J. (1994) 7(3):431-436.","journal-title":"Eur"},{"key":"e_1_3_1_20_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa042976"},{"key":"e_1_3_1_21_1","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(97)06405-2"},{"key":"e_1_3_1_22_1","first-page":"103","volume":"164","author":"MOGULKOC","year":"2001","unstructured":"MOGULKOC N, BRUTSCHE MH, BISHOP PW et al.: Pulmonary function in idiopathic pulmonary fibrosis and referral for lung transplantation. Am. J. Respir. Crit. Care Med. (2001) 164(1):103-108.","journal-title":"Am. J."},{"key":"e_1_3_1_23_1","first-page":"211","volume":"289","author":"IYER","year":"1999","unstructured":"IYER SN, GURUJEYALAKSHMI G, GIRI SN: Effects of pirfenidone on procollagen gene expression at the transcriptional level in bleomycin hamster model of lung fibrosis. J. Pharmacol. Exp. Ther. (1999) 289(1):211-218.","journal-title":"J."},{"key":"e_1_3_1_24_1","first-page":"119","volume":"204","author":"MISRA","year":"2000","unstructured":"MISRA HP, RABIDEAU C: Pirfenidone inhibits NADPH-dependent microsomal lipid peroxidation and scavenges hydroxyl radicals. Mol. Cell Biochem. (2000) 204(1-2):119-126.","journal-title":"Mol. Cell"},{"key":"e_1_3_1_25_1","first-page":"177","volume":"446","author":"NAKAZATO","year":"2002","unstructured":"NAKAZATO H, OKU H, YAMANE S, TSURUTA Y, SUZUKI R: A novel anti-fibrotic agent pirfenidone suppresses tumor necrosis factor-\u03b1 at the translational level. Eur. J. Pharmacol. (2002) 446(1-3):177-185.","journal-title":"Eur"},{"key":"e_1_3_1_26_1","first-page":"584","volume":"37","author":"DI SARIO","year":"2002","unstructured":"DI SARIO A, BENDIA E, SVEGLIATI-BARONI G et al.: Effect of pirfenidone on rat hepatic stellate cell proliferation and collagen production. J. Hepatol. (2002) 37(5):584-591.","journal-title":"J."},{"key":"e_1_3_1_27_1","first-page":"453","volume":"14","author":"HEWITSON","year":"2001","unstructured":"HEWITSON TD, KELYNACK KJ, TAIT MG et al.: Pirfenidone reduces in vitro rat renal fibroblast activation and mitogenesis. J. Nephrol. (2001) 14(6):453-460.","journal-title":"J."},{"key":"e_1_3_1_28_1","doi-asserted-by":"publisher","DOI":"10.1023\/A:1007068313370"},{"key":"e_1_3_1_29_1","doi-asserted-by":"publisher","DOI":"10.3109\/01902149809046058"},{"key":"e_1_3_1_30_1","first-page":"779","volume":"125","author":"IYER","year":"1995","unstructured":"IYER SN, WILD JS, SCHIEDT MJ et al.: Dietary intake of pirfenidone ameliorates bleomycin-induced lung fibrosis in hamsters. J. Lab. Clin. Med. (1995) 125(6):779-785.","journal-title":"J. Lab."},{"key":"e_1_3_1_31_1","first-page":"166","volume":"7","author":"LASKY","year":"2004","unstructured":"LASKY J: Pirfenidone. IDrugs (2004) 7(2):166-172.","journal-title":"IDrugs"},{"key":"e_1_3_1_32_1","first-page":"167","volume":"446","author":"OKU","year":"2002","unstructured":"OKU H, NAKAZATO H, HORIKAWA T, TSURUTA Y, SUZUKI R: Pirfenidone suppresses tumor necrosis factor-\u03b1, enhances interleukin-10 and protects mice from endotoxic shock. Eur. J. Pharmacol. (2002) 446(1-3):167-176.","journal-title":"Eur"},{"key":"e_1_3_1_33_1","first-page":"L311","volume":"276","author":"GURUJEYALAKSHMI","year":"1999","unstructured":"GURUJEYALAKSHMI G, HOLLINGER MA, GIRI SN: Pirfenidone inhibits PDGF isoforms in bleomycin hamster model of lung fibrosis at the translational level. Am. J. Physiol. Lung Cell Mol. Physiol. (1999) 276(2):L311-L318.","journal-title":"Am. J."},{"key":"e_1_3_1_34_1","first-page":"A621","volume":"167","author":"IYER","year":"2003","unstructured":"IYER S, DU X, NORRIS C, MARGOLIN SB, GIRI SN: Effects of pirfenidone on inflammatory and anti-inflammatory cytokines, CD4 and CD8 T-cells and nitric oxide levels in bronchoalveolar lavage fluid in bleomycin-mouse model of pulmonary fibrosis. Am. J. Respir. Crit. Care Med. (2003) 167:A621.","journal-title":"Am. J."},{"key":"e_1_3_1_35_1","first-page":"57","volume":"24","author":"KAKUGAWA","year":"2004","unstructured":"KAKUGAWA T, MUKAE H, HAYASHI T et al.: Pirfenidone attenuates expression of HSP47 in murine bleomycin-induced pulmonary fibrosis. Eur. Respir. J. (2004) 24(1):57-65.","journal-title":"Eur"},{"key":"e_1_3_1_36_1","first-page":"125","volume":"90","author":"KEHRER","year":"1997","unstructured":"KEHRER JP, MARGOLIN SB: Pirfenidone diminishes cyclophosphamide-induced lung fibrosis in mice. Toxicol. Lett. (1997) 90(2-3):125-132.","journal-title":"Toxicol"},{"key":"e_1_3_1_37_1","doi-asserted-by":"publisher","DOI":"10.1093\/toxsci\/kfg167"},{"key":"e_1_3_1_38_1","first-page":"A216","volume":"167","author":"ZHOU","year":"2003","unstructured":"ZHOU H, LATHAM CW, KAZEMFAR K, MARGOLIN SB, VISNER GA: Pirfenidone inhibits the development of obliterative bronchiolitis in a mouse tracheal transplant model. Am. J. Respir. Crit. Care Med. (2003) 167:A216.","journal-title":"Am. J."},{"key":"e_1_3_1_39_1","doi-asserted-by":"publisher","DOI":"10.2169\/internalmedicine.41.1118"},{"key":"e_1_3_1_40_1","first-page":"1061","volume":"159","author":"RAGHU","year":"1999","unstructured":"RAGHU G, JOHNSON WC, LOCKHART D, MAGETO Y: Treatment of idiopathic pulmonary fibrosis with a new antifibrotic agent, pirfenidone: results of a prospective, open-label Phase II study. Am. J. Respir. Crit. Care Med. (1999) 159(4 Part 1):1061-1069.","journal-title":"Am. J."},{"key":"e_1_3_1_41_1","first-page":"1040","volume":"171","author":"AZUMA","year":"2005","unstructured":"AZUMA A, NUKIWA T, TSUBOI E et al.: Double-blind, placebo-controlled trial of pirfenidone in patients with idiopathic pulmonary fibrosis. Am. J. Respir. Crit. Care Med. (2005) 171(9):1040-1047.","journal-title":"Am. J."},{"key":"e_1_3_1_42_1","doi-asserted-by":"publisher","DOI":"10.1016\/S1096-7192(02)00044-6"},{"key":"e_1_3_1_43_1","doi-asserted-by":"publisher","DOI":"10.7326\/0003-4819-134-2-200101160-00015"},{"key":"e_1_3_1_44_2_1","unstructured":"http:\/\/www.clinicaltrials.gov\/ct\/show\/ nct00001959?order=3: Pirfenidone to treat kidney disease (focal segmental glomerulosclerosis) trial."},{"key":"e_1_3_1_44_3_1","unstructured":"http:\/\/www.clinicaltrials.gov\/ct\/show\/ nct00076102?order=5: Pirfenidone in children and young adults with neurofibromatosis type I and progressive plexiform neurofibromas trial."},{"key":"e_1_3_1_44_4_1","unstructured":"http:\/\/www.clinicaltrials.gov\/ct\/show\/ nct00105391?order=4: Pirfenidone to treat kidney disease in patients with diabetes trial."},{"key":"e_1_3_1_44_5_1","unstructured":"http:\/\/www.clinicaltrials.gov\/ct\/show\/ nct00287729?order=1: Safety and efficacy of pirfenidone in patients with idiopathic pulmonary fibrosis trial."}],"container-title":["Expert Opinion on Investigational Drugs"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.tandfonline.com\/doi\/pdf\/10.1517\/13543784.15.7.823","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,3,6]],"date-time":"2026-03-06T02:49:31Z","timestamp":1772765371000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.tandfonline.com\/doi\/full\/10.1517\/13543784.15.7.823"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2006,6,21]]},"references-count":46,"journal-issue":{"issue":"7","published-print":{"date-parts":[[2006,7]]}},"alternative-id":["10.1517\/13543784.15.7.823"],"URL":"https:\/\/doi.org\/10.1517\/13543784.15.7.823","relation":{},"ISSN":["1354-3784","1744-7658"],"issn-type":[{"value":"1354-3784","type":"print"},{"value":"1744-7658","type":"electronic"}],"subject":[],"published":{"date-parts":[[2006,6,21]]}}}